Ladenburg Thalmann analyst, Wangzhi Li, reiterated his Buy rating on shares of Trillium Therapeutics (NASDAQ: TRIL) after the company updated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE